---
title: "Rexulti (brexpiprazole) in major depressive disorder: Specific populations questions"
description: "Specific populations questions on Rexulti (brexpiprazole) in major depressive disorder, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Pediatric use. Questions: Is Rexulti approved for children or teens with depression? How should Rexulti be dosed in adults 65 and older with depression? What is the maximum Rexulti dose for depression with liver impairment? What is the maximum Rexulti dose for depression with kidney impairment? 4 questions quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/rexulti--major-depressive-disorder/specific-populations"
published: "2026-11-13T03:43:41-05:00"
modified: "2026-11-14T01:54:55-05:00"
---

# Rexulti (brexpiprazole) in major depressive disorder: Specific populations questions

Manufacturer: Otsuka America Pharmaceutical, Inc.; Lundbeck  
Prescribing information: [Rexulti](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf)

Specific populations questions that apply to every indication of Rexulti are on [Rexulti (brexpiprazole), all indications: Specific populations](https://www.evicenter.com/medical-information/rexulti/specific-populations).

## Pediatric use

<a id="rexulti-pediatric-depression"></a>

### Is Rexulti approved for children or teens with depression?

> “The safety and effectiveness of REXULTI for treatment of major depressive disorder have not been 
> established in pediatric patients. Antidepressants increased the risk of suicidal thoughts and behaviors in 
> pediatric patients [see Boxed Warning, Warnings and Precautions (5.2)].”

Source: [REXULTI: Prescribing information, page 22, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=22)

## Specific populations

<a id="rexulti-older-adults"></a>

### How should Rexulti be dosed in adults 65 and older with depression?

> “Of the total number of REXULTI-treated patients in the clinical studies for the adjunctive therapy to 
> antidepressants for MDD and for schizophrenia, 248 (3%) were 65 years of age and older (which included 
> 45 (18%) patients who were 75 years of age and older). Clinical studies of REXULTI in these patients did not 
> include sufficient numbers of patients 65 years of age and older to determine whether they respond differently 
> from younger adult patients. In general, dosage selection for the treatment of MDD or schizophrenia in a 
> geriatric patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater 
> frequency of decreased hepatic, renal, and cardiac function, concomitant diseases, and other drug therapy.”

Source: [REXULTI: Prescribing information, page 23, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=23)

Note: The label reports the MDD and schizophrenia studies together in this passage.

<a id="rexulti-liver-impairment"></a>

### What is the maximum Rexulti dose for depression with liver impairment?

> “The maximum recommended dosage in patients with moderate to severe hepatic impairment (Child-Pugh 
> score ≥7) is [see Use in Specific Populations (8.7), Clinical Pharmacology (12.3)]:”

Source: [REXULTI: Prescribing information, page 4, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=4)

> “2 mg orally once daily in patients with MDD or agitation associated with dementia due to Alzheimer’s 
> disease”

Source: [REXULTI: Prescribing information, page 4, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=4)

> “The maximum recommended dosage in patients with moderate to severe hepatic impairment (Child-Pugh 
> score ≥7) is lower than those with mild hepatic impairment and those with normal hepatic function [see Dosage 
> and Administration (2.4)]. Patients with moderate to severe hepatic impairment generally had higher exposure 
> to brexpiprazole than patients with normal hepatic function [see Clinical Pharmacology (12.3)]. Greater 
> exposure may increase the risk of REXULTI-associated adverse reactions.”

Source: [REXULTI: Prescribing information, page 24, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=24)

<a id="rexulti-kidney-impairment"></a>

### What is the maximum Rexulti dose for depression with kidney impairment?

> “The maximum recommended dosage in patients with creatinine clearance CrCl<60 mL/minute is [see Use in 
> Specific Populations (8.8), Clinical Pharmacology (12.3)]:”

Source: [REXULTI: Prescribing information, page 4, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=4)

> “2 mg orally once daily in patients with MDD or agitation associated with dementia due to Alzheimer’s 
> disease”

Source: [REXULTI: Prescribing information, page 4, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=4)

> “The maximum recommended dosage in patients with CrCl<60 mL/minute is lower than those with mild renal 
> impairment and those with normal renal function [see Dosage and Administration (2.6)]. Patients with renal 
> impairment had higher exposure to brexpiprazole than patients with normal renal function [see Clinical 
> Pharmacology (12.3)]. Greater exposure may increase the risk of REXULTI-associated adverse reactions.”

Source: [REXULTI: Prescribing information, page 24, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=24)

## Related pages
- [Medical information: Rexulti (brexpiprazole): Major depressive disorder](https://www.evicenter.com/medical-information/rexulti--major-depressive-disorder)
- [Indication](https://www.evicenter.com/medical-information/rexulti--major-depressive-disorder/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/rexulti--major-depressive-disorder/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/rexulti--major-depressive-disorder/safety)
- [Drug interactions](https://www.evicenter.com/medical-information/rexulti--major-depressive-disorder/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/rexulti--major-depressive-disorder/dosing-and-administration)
- [Access and coverage](https://www.evicenter.com/medical-information/rexulti--major-depressive-disorder/access-and-coverage)
